Gyre Therapeutics, Inc
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases. Its business combines an established China commercial franchise, anchored by ETUARY® (pirfenidone), with U.S.-based development of Hydronidone (F351) for liver fibrosis and other late-stage fibrosis programs.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved and marketed products sold primarily in the PRC, including ETUARY® and other fibrosis medicines.
Products acquired through licensing or marketing authorization, such as Etorel®, that expand the commercial portfolio.
Clinical-stage small-molecule candidates led by Hydronidone (F351) for liver fibrosis and related indications.
Customers
Gyre sells primarily to distributors, which are its direct customers and resell into hospitals, other medical institutions, and pharmacies. The company also relies on medical experts and academic promotion to drive physician awareness and support uptake of ETUARY® and future fibrosis products. In the U.S., the customer base is currently development-oriented rather than commercial, as the company advances clinical programs and regulatory filings.
Buy ETUARY®, Etorel® and other products directly from Gyre and resell them into the healthcare channel; they are the company's direct revenue customers.
End-market channel for fibrosis therapies where physicians prescribe and administer products for pulmonary and other fibrotic diseases.
Retail and institutional pharmacy outlets that receive products from distributors and expand patient access.
Influence prescribing behavior through conferences, seminars, and clinical education around ETUARY® and pipeline assets.
Support U.S. and PRC development programs for Hydronidone and other candidates through clinical studies.
Strategy
Gyre's strategy is to use its established China commercial base to fund and de-risk a broader fibrosis pipeline, especially Hydronidone in the United States. It is also expanding its approved-product footprint through licensing and indication expansion, as shown by the Etorel® agreement, while building a more diversified portfolio across fibrosis and inflammatory diseases.
A successful U.S. program would diversify the company beyond China commercial sales and create a larger addressable market.
ETUARY® and related products provide the operating base and commercial know-how needed to fund development.
A wider portfolio reduces concentration risk and increases the chance of multiple approved products.
Geography
Gyre operates a dual-base model with commercial activity concentrated in the PRC and development and corporate functions in the United States. The PRC is the core revenue engine through ETUARY® and distributor-led sales, while San Diego serves as the U.S. headquarters for G&A and clinical development. This structure exposes the company to China regulatory, reimbursement, and channel risks while also tying future growth to U.S. clinical execution.
Risks
Gyre remains highly dependent on ETUARY® and the PRC commercial channel, so any loss of share, pricing pressure, or distributor disruption could materially affect results. Development risk is also meaningful because Hydronidone and other pipeline assets must clear clinical, regulatory, manufacturing, and funding hurdles in both the U.S. and China. The company also faces typical biopharma risks around supply chain reliability, GMP compliance, and cross-border regulatory exposure.
- Dependence on ETUARY® salesImpact: HighLikelihood: Medium
A large share of revenue is tied to one marketed product in a competitive fibrosis market.
Exposure: PRC commercial business
- Clinical development failureImpact: HighLikelihood: Low
Hydronidone and other candidates may not demonstrate efficacy, safety, or regulatory approvability.
Exposure: U.S. and PRC pipeline
- Distributor concentration and channel instabilityImpact: MediumLikelihood: Medium
Direct customers are distributors, so partner consolidation or weak execution can affect product flow and collections.
Exposure: PRC sales network
- Supply chain and manufacturing disruptionImpact: MediumLikelihood: Medium
The company relies on third-party suppliers and GMP-compliant manufacturing for commercial and trial products.
Exposure: Raw materials and contract manufacturing
- PRC-U.S. regulatory and geopolitical exposureImpact: MediumLikelihood: Medium
Cross-border operations can be affected by changes in regulation, approvals, data transfer, or bilateral relations.
Exposure: China and United States
Accounting
Judgemental itemsSales are recognized when control transfers on delivery, so distributor shipment timing can shift revenue between periods.
Impact: Quarterly revenue comparability
Etorel® and Nintedanib arrangements include upfront and future payments based on sales or milestones.
Impact: Cash flow, accruals, and contingent liabilities
Clinical and development spending is expensed as incurred, which can create volatility as programs advance.
Impact: Operating loss and burn rate
Acquired product rights and related assets may need impairment or fair-value reassessment if prospects change.
Impact: Balance sheet carrying values
Similar listed companies
Publicly listed companies with a comparable business focus.
aTyr Pharma, Inc
ATYR · Biological Products, (No Diagnostic Substances)
aTyr Pharma is a U.S.-based biotechnology company focused on discovering and developing protein-based therapeutics derived from tRNA synthetase biology.
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
Lyra Therapeutics, Inc.
LYRA · Surgical & Medical Instruments & Apparatus
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Last updated: 24/09/2026